登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>VCAM-1 >GMP-VC1H25

GMP Human VCAM-1 Protein, Fc Tag

PG version VC1-H5253 is now available for seamless transition.
热门推荐产品:配套残留检测试剂盒

优势特色(Features)

  1. Designed under ISO 9001:2015 and ISO 13485:2016
  2. Manufactured and QC tested under a GMP compliance factory
  3. Animal-Free materials
  4. Beta-lactam materials free
  5. Batch-to-batch consistency
  6. Stringent quality control tests

表达区间及表达系统(Source)

GMP Human VCAM-1 Protein, Fc Tag (GMP-VC1H25) is expressed from human 293 cells (HEK293). It contains AA Phe 25 - Glu 698 (Accession # P19320-1).

Predicted N-terminus: Phe 25

Request for sequence

蛋白结构(Molecular Characterization)

VCAM-1 Structure

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 100.7 kDa. The protein migrates as 126 kDa±5 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 10 EU/mg by the LAL method.

蛋白A残留(Protein A)

<5 ppm of protein tested by ELISA.

宿主蛋白残留(Host Cell Protein)

<0.5 ng/µg of protein tested by ELISA.

宿主核酸残留(Host Cell DNA)

<0.02 ng/μg of protein tested by qPCR.

无菌(Sterility)

The sterility testing was performed by membrane filtration method described in CP<1101>, USP<71> and Eur. Ph. 2.6.1.

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with protectants.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with blue ice, please inquire the shipping cost.

存储(Storage)

Upon receipt, store it immediately at -20°C or lower for long term storage.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 5 years in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

VCAM-1 SDS-PAGE

GMP Human VCAM-1 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-ELISA

VCAM-1 ELISA

Immobilized GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) with a linear range of 2-63 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-SPR

VCAM-1 SPR

GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) captured on Protein A Chip can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with an affinity constant between 1.00 nM - 50.0 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol

 

应用数据(Application Data)

VCAM-1 APPLICATION DATA

CD34+ CD45+ hematopoietic cells were seeded on GMP Human DLL4 Protein, Fc Tag (Flagship) (Cat. No. GMP-DL4H27) and GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) coated plates and differentiated for 14 days, then flow cytometry was used to detect the expression of T-cell progenitor markers, CD5 and CD7. GMP Human DLL4 Protein, Fc Tag (Flagship) (Cat. No. GMP-DL4H27) and GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) together with other growth factors could induce the high percentage of CD7+ and CD5+ CD7+ T-cell progenitors formation.

VCAM-1 APPLICATION DATA

The Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) combined with GMP Human DLL4 Protein, Fc Tag (Cat. No. GMP-DL4H28), GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) coating on the plate could efficiently induce hematopoietic stem cells differentiation to NK cells, with high expression of CD56+ CD3-.

 

稳定性(Stability)

VCAM-1 STABILITY

The Cell based assay shows that GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) is stable at 37℃ for 24 hours.

VCAM-1 STABILITY

The SPR based assay shows that GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) is stable at 4℃ for 180 days.

VCAM-1 STABILITY

The Cell based assay shows that GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) is stable after freezing and thawing 3 times.

VCAM-1 STABILITY

The SPR based assay shows batch-to-batch consistency between Acro's GMP and PG VCAM-1.

MANUFACTURING SPECIFICATIONS

ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP <92> Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.


ACROBiosystems Quality Management System Contents:

  1. Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory.
  2. Animal-Free materials
  3. Materials purchased from the approved suppliers by QA
  4. ISO 5 clean rooms and automatic filling equipment
  5. Qualified personnel
  6. Quality-related documents review and approve by QA
  7. Fully batch production and control records
  8. Equipment maintenance and calibration
  9. Validation of analytical procedures
  10. Stability studies conducted
  11. Comprehensive regulatory support files

Request For Regulatory Support Files(RSF)  Request For DMF


ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

  1. SDS-PAGE
  2. Protein content
  3. Endotoxin level
  4. Residual Host Cell DNA content
  5. Residual Host Cell Protein content
  6. Biological activity analysis
  7. Microbial testing
  8. Mycoplasma testing
  9. In vitro virus assay
  10. Residual moisture
  11. Batch-to-batch consistency


DISCLAIMER

ACROBiosystems GMP grade products are designed for research, manufacturing use or ex vivo use. CAUTION: Not intended for direct human use.

TERMS AND CONDITIONS

All products are warranted to meet ACROBiosystems Inc.’s (“ACRO”) published specifications when used under normal laboratory conditions.


ACRO DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, ACRO DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

NOT WITH STANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN ACRO AND PURCHASER FOR THE PURCAHSE OF THE PRODUCTS, ACRO’S TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO ACRO FOR THE RELEVANT PRODUCTS. IN NO EVENT WILL ACRO BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

END USER TERMS OF USE OF PRODUCT

The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

The End User is aware that ACROBiosystems Inc. and its affiliate (“ACRO”) sell GMP grade products designed for research, manufacturing use or ex vivo use and not intended for human in vivo applications. The End User further agrees, as a condition of the sales of ACRO’s GMP grade products that: a) the End User will not use this GMP grade product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the applicable review board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Vascular cell adhesion protein 1 (VCAM1) is also known as CD106, INCAM-100 and L1CAM, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. VCAM1 / CD106 contains 7 Ig-like C2-type (immunoglobulin-like) domains. CD106 / VCAM-1 is expressed on inflammed vascular endothelium, as well as on macrophage-like and dendritic cell types in both normal and inflammed tissue. L1CAM / VCAM-1 is Important in cell-cell recognition and appears to function in leukocyte-endothelial cell adhesion. CD106 / VCAM1 interacts with the beta-1 integrin VLA4 on leukocytes, and mediates both adhesion and signal transduction. The VCAM1 / VLA4 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation. INCAM-100 / VCAM1 binds to ECMV-D capsid proteins and acts as a receptor for this virus.

 

前沿进展

Endothelial Dysfunction Markers Correlate with the Time Since Completion of Tuberculosis Treatment and the Number of Previous Tuberculosis Episodes
Jumaar, Jacobs, Payne et al
Infect Dis Rep (2025) 17 (2)
Abstract: Background: Despite "successful" treatment, some lung tuberculosis (TB) patients develop long-term lung impairments that includes damage to the parenchyma and reduced function, which may predispose them to diseases like pulmonary hypertension. However, this is not well understood. Therefore, we investigated whether previous or current TB patients would display elevated biomarkers of endothelial dysfunction and vascular remodeling. Methods: We performed assays for ADMA, VCAM-1, VEGF, angiopoietin-1, TBARS, NT-pro-BNP, and cardiac troponin-I. We further stratified the patients based on 1, 2, 3, and >3 previous TB episodes, and 1-5 yrs, 5-10 yrs, 10-15 yrs and >15 yrs after the last TB treatment completion. We also assessed correlations between the biomarkers and the number of previous TB episodes or the time since the completion of the last TB treatment. Results: ADMA was 70 times higher, VEGF was 2000 times higher and angiopoietin-1 was 6500 times higher than the normal range. NT-pro-BNP and cardiac troponin-I were undetected, and TBARS levels were low. There was a positive linear relationship between the number of previous TB episodes and angiopoietin-1, and between VEGF and the number of previous TB episodes. ADMA, VCAM-1 and TBARS exhibited a weak and negative linear association with the number of previous TB episodes. A negligible negative linear association was observed between the time since the completion of the last TB treatment and angiopoietin-1, VEGF and ADMA. Conclusions: Therefore, having >1 previous TB episode, despite the successful completion of TB treatment, associates with an increased risk of endothelial dysfunction/angiogenesis or vascular remodeling.
Profile of soluble cell adhesion molecules as potential biomarkers in the cardiac stages of chronic Chagas disease
Vaitkevicius-Antão, Silva, Barros et al
Front Immunol (2025) 16, 1541860
Abstract: Chagas cardiomyopathy is the most severe chronic manifestation and leading cause of mortality in the disease. Chronic inflammation, resulting from persistent infection by T. cruzi, leads to continuous immune system activation in patients with Chagas disease. The knowledge of immunological aspects can be important for the identification of biomarkers capable of indicating parasitological cure or clinical progression provides for physician's valuable tools for improved clinical evaluation. Soluble cell adhesion molecules (sCAMs) have been applied in other disease like potential biomarkers. Thus, the aim of this study was to evaluate the levels of soluble cell adhesion molecules in chronic patients with different stages of Chagas heart disease progression. Sera from 303 individuals, classified according to cardiac involvement and left ventricular dysfunction, were used for cell adhesion molecules quantification (sVCAM-1, sP-selectin, sE-selectin and sL-selectin) and it was measured using the Cytometric Bead Array. We found that sCAMs demonstrated good performance in differentiating patients in the indeterminate phase from negative individuals or those in the mild cardiac phase, as well as patients with mild from those with severe cardiomyopathy, and cardiac patients non-infected versus infected (severe cardiomyopathy). Therefore, sCAMs may serve as potential biomarkers for the diagnosis and prognosis of chronic cardiac patients with Chagas disease.Copyright © 2025 Vaitkevicius-Antão, Silva, Barros, Costa-Oliveira, Torreão, Silva, Martins, Carrazone, Oliveira, Medeiros, Rabello and Lorena.
Prodigiosin Loaded SN-PB@PG NPs-Based Multimodal Therapy for the Healing of Bacterial Infected Chronic Wounds
Wu, Chang, Li et al
Adv Healthc Mater (2025)
Abstract: Healing of infected chronic wounds faces dual challenges: persistent inflammation and impaired angiogenesis. To address these, SN-PB@PG nanocomplexes were prepared by hybridisation of nitroprusside (SNP) with Prussian blue (SN-PB NPs) and loaded with prodigiosin (PG). Under near-infrared (NIR) irradiation, SN-PB NPs generated mild hyperthermia, facilitating the release of nitric oxide (NO) and PG to combat bacterial biofilms and multidrug-resistant pathogens. The in vivo assay using diabetic infected wounds demonstrated that SN-PB@PG NPs with NIR reduced the wound area to 10.6% by the 11th day, which is superior to that of control group (29.6%). In the flap transplantation experiments, the data showed SN-PB@PG NPs with NIR group only have a necrobiosis of 3.8% of flaps on the 8th day, which is superior to 31.3% of the control group. Additionally, the release of NO promoted vascular regeneration by up-regulating vascular endothelial growth factor (VEGF) and platelet endothelial cell adhesion molecule-1 (CD31), and regenerated sarcomeric tissue by down-regulating MMP-9. The results indicated that the combination of SN-PB@PG NPs with gas and photothermal therapy exerted a combined antibacterial and wound healing effect. Compared to traditional clinical methods such as surgical debridement and hyperbaric oxygen therapy, this new strategy efficiently addresses issues of infection and healing, which is convenient for clinical application.© 2025 Wiley‐VCH GmbH.
Specnuezhenide and ecliptasaponin A from Ligustrum lucidum Ait and Ecliptae Herba improved premature ovarian failure by targeting the ESR1
Xu, Lei, Li et al
J Pharmacol Sci (2025) 158 (1), 13-26
Abstract: This study was designed to investigate the role of Ligustrum lucidum Ait and Ecliptae Herba on premature ovarian failure (POF) and the underlying mechanisms. In the POF mouse model constructed using cyclophosphamide (CTX), Ligustrum lucidum Ait and Ecliptae Herba increased ovarian index and estradiol (E2) levels and curtailed motility and follicle-stimulating hormone (FSH). Ligustrum lucidum Ait and Ecliptae Herba alleviated ovarian pathological damage in POF mice and promoted the expression of ovarian CD31 and Vascular Endothelial Growth Factor A (VEGFA). Through high-performance liquid chromatography-mass spectrometry (HPLC-MS) and network pharmacology, Specnuezhenide and ecliptasaponin A were identified as the key components of Ligustrum lucidum Ait and Ecliptae Herba in anti-POF action. The important target associated with these components is Estrogen Receptor (ESR) 1. Molecular docking and in vitro experiments showed that Specnuezhenide and ecliptasaponin A can both bind to the ESR protein; knocking down ESR1 inhibited the anti-apoptotic effect of Specnuezhenide and ecliptasaponin A on CTX-induced POF cells. In conclusion, the key components of Ligustrum lucidum Ait and Ecliptae Herba that alleviate POF are Specnuezhenide and ecliptasaponin A, which improve the condition by upregulating ESR1.Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.
Showing 1-4 of 23180 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
法规支持文档(RSF)
一级-产品资质文档(免费)
二级-独特的质量和全性文档(付费)
点击咨询和申请
VCAM-1靶点信息
英文全称:Vascular cell adhesion molecule 1
中文全称:血管细胞粘附分子1
种类:Homo sapiens
上市药物数量:2详情
临床药物数量:1详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细
相关产品
View All VCAM-1

消息提示

请输入您的联系方式,再点击提交!

确定